# Verana Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/verana-health

- Industry: Healthcare IT
- Headquarters: San Francisco, US
- Website: www.veranahealth.com
- Total disclosed funding: $291M
- Latest round: Series E (Jan 14, 2022)
- Investors on record: 14

## About

Verana Health, Inc., based in the US, specializes in leveraging real-world data to provide advanced analytics solutions for healthcare providers and researchers, focusing primarily on ophthalmic and urological conditions.Founded in 2008 and headquartered in San Francisco, US, Verana Health, Inc. delivers real-world data solutions tailored for the healthcare sector. The company has successfully completed various funding rounds, with the most recent being a Series E round in January 2022, raising USD 150 mn from investors including Johnson & Johnson Innovation and Novo Holdings. Marc Berger serves as the CEO, guiding the company through its growth and product development strategy.Verana Health specializes in harnessing real-world data (RWD) through its advanced analytics products and services. The company offers comprehensive data solutions that integrate secure artificial intelligence (AI) and machine learning (ML) capabilities to extract actionable insights from electronic health records (EHRs). Their core offerings are designed to support pharmaceutical companies and clinical research organizations in optimizing clinical development, health economics and outcomes research (HEOR), and commercial strategies. Verana Health collaborates with leading medical societies to enhance research capabilities, making their solutions indispensable for healthcare providers and researchers focusing on ophthalmic and urological conditions. The company serves a diverse client base, including major pharmaceutical firms and clinical research entities across the United States and internationally, with a significant emphasis on leveraging extensive clinical databases for timely and impactful insights.Verana Health generates revenue primarily through business-to-business (B2B) transactions, offering data-as-a-service (DaaS) and software-as-a-service (SaaS) solutions to its clients. The company’s revenue model includes subscription agreements and collaborative partnerships, allowing clients to access and utilize extensive datasets for research and clinical decision-making. These arrangements facilitate ongoing access to real-time data and insights that are crucial for the development of clinical strategies and market expansion. With a focus on high-value therapeutic areas, Verana Health’s flagship products, such as its Qdata platforms, are offered to pharmaceutical companies and healthcare organizations to inform their clinical and commercial initiatives. The pricing structure for these services is tailored according to the specific needs and scale of the partnership, aligning with the comprehensive solutions provided to support various healthcare research and development efforts.Following the Series E funding round in January 2022, which raised USD 150 mn, Verana Health plans to advance its life sciences product and service strategy across the drug lifecycle. The company aims to enhance its value proposition for healthcare providers participating in its real-world data network and expand its data footprint through partnerships with medical societies. Future initiatives include the development of new analytics tools designed for upcoming therapeutic areas and the potential expansion into additional international markets by 2024.

## Funding rounds

- Series E, Jan 14, 2022, $150M — Johnson & Johnson Innovation, Novo Holdings, Merck Global Health Innovation Fund, GV, Casdin Capital, Breyer Capital, THVC
- Series D, Jan 29, 2020, $20M — Bain Capital, GV, Casdin Capital
- Series D, May 15, 2019, $80M — Bain Capital, GV, Casdin Capital, Define Ventures
- Series C, Jul 6, 2018, $33M — GV, Biomatics Capital Partners, Lagunita BioSciences, GE Ventures
- Series B, Feb 9, 2015, $7.8M — Biosys Capital, Waycross Ventures, Lagunita BioSciences, GE Ventures

## Investors

- Biosys Capital — Series B
- Waycross Ventures — Series B
- Lagunita BioSciences — Series B, Series C
- GE Ventures — Series B, Series C
- GV (https://capitalatlas.ai/funds/gv) — Series C, Series D, Series E
- Biomatics Capital Partners (https://capitalatlas.ai/funds/biomatics-capital-partners) — Series C
- Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Series D
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series D, Series E
- Define Ventures (https://capitalatlas.ai/funds/define-ventures) — Series D
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series E
- Novo Holdings — Series E
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series E
- Breyer Capital (https://capitalatlas.ai/funds/breyer-capital) — Series E
- THVC (https://capitalatlas.ai/funds/thvc) — Series E